Background: Atacicept targets B-cell stimulating factors BLyS and APRIL, and has shown evidence of clinical response in SLE. Objectives: Exploration of atacicept efficacy and safety in a pre-defined subpopulation of SLE patients with high disease activity (HDA, SLEDAI-2K ≥10 at Screening) in the phase IIb ADDRESS II study (NCT01972568). Methods: Autoantibody positive patients on standard of care therapy were randomized 1:1:1 to double-blind weekly SC injections of atacicept 75 or 150 mg or placebo (PBO) for 24 weeks. Analyses of the HDA subpopulation are now reported. Results: 52% of the ITT population had HDA (n=158: 52 PBO; 55 atacicept 75 mg; 51 atacicept 150 mg). 92% were female, 67% were white, and baseline characteristics were balanced between groups. At week 24 (Table 1; Figure 1 ), the proportion of SLE Responder Index (SRI)-4 (p<0.05) and SRI-6 (p<0.005) responses was greater with atacicept 150 mg vs PBO. BICLA response rate was higher with both doses (p<0.05). More patients achieved SLEDAI-2K ≤2 with atacicept 150 mg vs PBO (p<0.01). Time to severe and moderate-severe flare was significantly reduced at both atacicept doses vs PBO (p<0.05). Patients in the quartile with the largest decline in serum IgG had the highest SRI-6 response
Results: At baseline, several blood cell types were lower for patients with SLEDAI ≥10, including naïve B cells, and memory T and B cells. In IFN-high patients, neutrophils, memory T cells, and plasmacytoid dendritic cells (pDCs) were significantly decreased. Anifrolumab led to significant increases in absolute numbers of T-cell subsets in the blood of IFN-high patients. In contrast, no significant changes were observed for IFN-low patients. Observed increases were within normal reference ranges. The alterations did not appear to be secondary to tapering of oral corticosteroids, as these cell types were not significantly different in PBO groups, regardless of tapering. Patients with ≥6-point SLEDAI reductions following anifrolumab demonstrated significant increases in total CD4 and CD8 T cells, and nonsignificant decreases in memory B cells. Significant increases in pDCs were also evident. Anifrolumab did not cause significant differences in other cell types measured. Conclusions: Memory T cell numbers, among other cell types, were significantly reduced in patients with SLEDAI ≥10 and those classified as IFN high at baseline. This suggests that, for patients with more severe disease, type I IFN may be involved in cell migration into the peripheral tissues from the blood. Consistent with this, we found that neutralization of type I IFN with anifrolumab promoted immigration and/or prevented emigration of potentially pathologic immune cells between the tissues and the blood. These data suggest that some effects observed following anifrolumab treatment might be a result of altering the migration patterns of T and other immune cells, which may partially explain its biological activity.
